A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
CUPERTINO, Calif., Aug. 21, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 - - Registrational RECOVER-2 trial in schizophrenia expected to initiate Q3 2024; topline data expected Q4 2025 - - European patent granted covering brilaroxazine use for treating pulmonary...
CUPERTINO, Calif., Aug. 06, 2024 -- -Similar patent has also been granted in Japan -Brilaroxazine has received Orphan Drug Designation for the treatment of idiopathic pulmonary fibrosis (IPF) Cupertino, Calif., August 6, 2024 - Reviva Pharmaceuticals Holdings, Inc....
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have...
CUPERTINO, Calif., May 29, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., May 28, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., May 21, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia - - Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia - - Topline data from 1-year open-label extension (OLE) trial expected...
- Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia - - Registrational RECOVER-2 trial expected to initiate Q2 2024; topline data expected Q3 2025 - - Topline data...
CUPERTINO, Calif., May 13, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., May 09, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia - - Initiation of registrational RECOVER-2 trial expected in the second quarter of 2024;...
- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia - - Topline data from 1-year...
CUPERTINO, Calif., March 28, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., March 26, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., March 11, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., March 07, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., Feb. 20, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Virtual event on Thursday, February 15, 2024 at 12:00 PM ET will feature KOLs Larry Ereshefsky, PharmD, BCPP, FCCP, of Follow the Molecule and Mark Opler, PhD, MPH of WCGCUPERTINO, Calif., Feb. 06, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva"...
CUPERTINO, Calif., Jan. 25, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, CA / January 10, 2024 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE) trial, and positive drug-drug interaction data supporting a differentiated profile for once-daily brilaroxazine - -...
CUPERTINO, Calif., Dec. 11, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., Nov. 30, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., Nov. 20, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., Nov. 16, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- RECOVER global Phase 3 trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine vs. placebo in schizophrenia - - Consistent...
- Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total score vs. placebo at week 4, p<0.001 - - Statistically significant...
Topline data for RECOVER trial on track for October 2023CUPERTINO, Calif., Sept. 25, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical...
CUPERTINO, Calif., Sept. 07, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- 402 patients completed enrollment across multiple sites in the US, Europe, and Asia - - Topline data for Phase 3 RECOVER study expected in October 2023 - - Completion of 1-year open-label extension clinical study expected in Q3 2024 - CUPERTINO, Calif., Aug. 17,...
- Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 - - Completion of 1-year open-label extension clinical trial for brilaroxazine in schizophrenia expected in Q3 2024 - CUPERTINO, Calif., Aug. 14, 2023...
CUPERTINO, Calif., July 31, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., June 26, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- Enrollment ongoing at multiple sites in the US, Europe, and Asia - - Multifaceted activity of serotonin-dopamine stabilizer brilaroxazine supports potential for improvement in schizophrenia symptoms as well as accompanying neuroinflammation - - Topline data for...
CUPERTINO, Calif., June 15, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF) Brilaroxazine improved survival and lung function, and reduced lung fibrosis and inflammation in a bleomycin-induced rodent...
Data reinforce brilaroxazine's differentiated clinical pharmacology and safety profile Brilaroxazine may be co-administered with other drugs metabolized by CYP3A inhibitors Metabolism and excretion profiles of brilaroxazine were similar across mice, canines, and...
CUPERTINO, Calif., May 19, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., May 18, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 - - Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model - -...
CUPERTINO, Calif., May 12, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model IND submission for brilaroxazine lipogel in psoriasis expected in 2024 Reviva has filed composition of matter...
CUPERTINO, Calif., May 04, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Multifaceted activity of brilaroxazine supports potential for improvement in behavioral symptoms as well as accompanying neuroinflammation This proof-of-concept data supported the initial clinical development of brilaroxazine and reinforces the clinical profile...
Virtual event on Tuesday, May 2, 2023 at 11:00am ET will feature key opinion leader (KOL) Larry Ereshefsky, PharmD, BCPP, FCCP, Chief Scientific Officer, Follow the MoleculeCUPERTINO, Calif., April 25, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH)...
CUPERTINO, Calif., April 20, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 - - Completed majority of non-clinical and clinical prelaunch measures for brilaroxazine New Drug Application (NDA) submission - -...
CUPERTINO, Calif., March 07, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Cupertino, Calif., Jan. 31, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...